The clinician’s guide to magnesium: physiology, deficiency, foods, and therapeutic uses

Intro

For U.S. health care professionals, the mineral discussed here occupies a unique intersection of nutrition, internal medicine, and acute care. It participates in hundreds of enzyme systems that govern energy metabolism, neuromuscular excitability, cardiac conduction, glucose handling, and bone remodeling. Yet nearly half of Americans fall short of estimated average requirements from foods and beverages, and clinical measurement remains imperfect serum values can be normal while total body stores are depleted [1]. This review synthesizes physiology, epidemiology, diagnostics, clinically relevant interactions, and therapeutic indications, with U.S.-specific guidance on intake, safety, and counseling.

Clinical Overview of Magnesium

The ion functions as a cofactor in >300 enzyme systems (e.g., ATP-dependent kinases), contributes to nucleic acid and glutathione synthesis, and modulates voltage-gated channels that control nerve transmission and muscle contraction [1,3]. Roughly 25 g reside in the adult body; 50–60% is in bone, the remainder is largely intracellular in muscle and soft tissues, and <1% circulates in serum under tight homeostatic control [1]. Homeostasis is maintained via intestinal absorption (mediated by channels such as TRPM6/TRPM7) and renal reclamation across the thick ascending limb and distal convoluted tubule [3].

Because serum represents a tiny compartment and is autoregulated, low circulating values reliably indicate deficiency, but normal values do not exclude tissue depletion, particularly in chronic disease or polypharmacy [1,5]. Clinically, this mineral is unusual: it is both a core nutrient requiring population-level attention (dietary shortfalls) and a parenteral drug with life‑saving roles in specific emergencies (e.g., torsades de pointes; eclampsia) [6,7].

Physiology and Homeostasis

At the cellular level, TRPM6/TRPM7 channels regulate epithelial uptake and intracellular balance; congenital or acquired dysfunction can precipitate hypomagnesemia with secondary hypocalcemia via impaired parathyroid hormone signaling [3]. The kidney governs daily balance by filtering and reabsorbing the majority of the filtered load; diuretics, calcineurin inhibitors, amphotericin B, cisplatin, and uncontrolled glycosuria can increase urinary wasting [1,3].

Normal laboratory reference intervals vary, but many authorities propose a lower cut‑off near 0.85 mmol/L (≈2.07 mg/dL) to avoid missing chronic latent deficiency states implicated in cardiometabolic risk [4]. Still, no single biomarker is ideal: serum is widely available but insensitive; alternative approaches (erythrocyte or ionized levels, 24‑hour urinary excretion, and magnesium loading tests) can add context but have limited standardization and availability [1,5].

U.S. Intake Recommendations and Status

U.S. RDAs (adults): 400–420 mg/day for men and 310–320 mg/day for women, with higher targets during pregnancy and lactation [1]. Importantly, the tolerable upper intake level (UL) for supplemental (non‑food) forms in adults is 350 mg/day, this UL does not apply to naturally occurring intake from foods and beverages [1]. National dietary surveillance (NHANES 2013–2016) indicates that about 48% of Americans fail to meet their estimated average requirement from food and beverages alone, with older adults and adolescents most affected; routine serum monitoring is not part of NHANES and is uncommon in clinical workflows [1]. Counseling toward nutrient-dense patterns consistent with the Dietary Guidelines for Americans can close typical gaps [1].

Deficiency: Prevalence, Risk Factors, and Pathophysiology

Sustained shortfalls and/or increased renal or gastrointestinal losses drive inadequacy. Higher‑risk groups include older adults, people with gastrointestinal disorders causing malabsorption or diarrhea, those with type 2 diabetes (osmotic diuresis and insulin resistance are contributory), chronic alcohol use, and individuals on medications that increase urinary wasting or reduce absorption [1]. Mechanistically, deficiency decreases cellular ATP stability, increases neuromuscular excitability, and perturbs calcium–potassium handling in excitable tissues; secondary hypokalemia and hypocalcemia are common due to renal potassium wasting and impaired parathyroid hormone action [1,3].

Clinical Manifestations and Differential

Early or mild depletion can present with anorexia, nausea, fatigue, and generalized weakness. Progressive deficits may produce paresthesias, cramps, carpopedal spasm, tremor, nystagmus, seizures, ventricular ectopy, and frank arrhythmia; ECG changes include prolonged PR, QRS, and QT intervals in severe states. Because symptoms overlap with calcium and potassium disorders often co‑present electrolyte panels and acid–base assessment are essential [1]. Consider concomitant causes (e.g., diuretic overuse, uncontrolled diabetes, proton pump inhibitor–associated malabsorption) and comorbid deficiencies (vitamin D) in the differential [1,16,22].

Assessment and Laboratory Interpretation

Serum total values (typical lab ranges ≈0.75–0.95 mmol/L) are specific for overt deficiency but insensitive for marginal depletion [1]. Several expert groups advocate raising the lower decision threshold to ≈0.85 mmol/L to reflect epidemiologic links between “low‑normal” levels and adverse outcomes [4]. Supplemental tests can help in persistent clinical suspicion: erythrocyte concentrations, ionized magnesium, 24‑hour urinary excretion (low intake vs renal wasting), or a loading test in specialized settings [1,5]. Practical approach: in symptomatic patients or those at high risk with compatible findings (e.g., refractory hypokalemia), treat presumptively while correcting contributors (diuretics, uncontrolled glycosuria, PPI exposure) and repleting co‑deficiencies (potassium, calcium, vitamin D) [1,5,22].

Interactions With Medications and Nutrients

Chelation in the gut reduces absorption of oral tetracyclines and fluoroquinolones; separate dosing (at least 2 hours before or 4–6 hours after) is recommended. Oral bisphosphonates should also be separated by ≥2 hours to protect absorption [1]. Chronic loop and thiazide diuretics increase urinary losses; potassium‑sparing agents decrease losses [1]. Long‑term PPI therapy has a well‑documented association with hypomagnesemia; monitoring is prudent in patients on prolonged courses, and some cases require PPI discontinuation to normalize values [22]. High‑dose zinc may impede absorption; vitamin D biology is tightly interwoven this mineral is required for hepatic 25‑hydroxylation and renal 1α‑hydroxylation, and deficiency can blunt vitamin D efficacy [1,16].

Therapeutic Applications Across Specialties

Cardiology (torsades de pointes and ventricular dysrhythmias). Intravenous use is guideline‑supported for torsades de pointes (long‑QT–associated polymorphic VT) and may be considered in specific scenarios during resuscitation; recommendations derive from the AHA adult advanced life support guidelines [7].

Obstetrics (preeclampsia/eclampsia). Parenteral magnesium sulfate is the standard for seizure prophylaxis and treatment in preeclampsia with severe features and eclampsia; ACOG cites substantial risk reduction demonstrated in large trials and endorses loading and maintenance protocols in appropriate settings [6].

Pulmonology (severe asthma exacerbation). Routine use is not recommended; however, for severe attacks that respond poorly to initial bronchodilator and steroid therapy in acute care, a single 2 g IV dose may be considered per contemporary international guidance [8].

Neurology (migraine prevention). Evidence supports a role as “probably effective” for prevention; the American Headache Society cites oral dosing in the 400–500 mg/day range (often as magnesium oxide) with attention to gastrointestinal tolerance and the UL for supplemental intake [9]. For emergency department management of acute migraine, parenteral use is variable; preventive use has the stronger evidence base [1,9].

Cardiometabolic health (blood pressure and glycemia). Multiple modern meta‑analyses indicate modest BP reductions, particularly at ≥400 mg/day over ≥12 weeks and in individuals with hypertension or low baseline status, with heterogeneity across trials [10,11]. Randomized trials and systematic reviews suggest improvements in insulin sensitivity and, in some subgroups with type 2 diabetes, small improvements in glycemic indices; guideline bodies remain cautious about routine supplementation absent deficiency [14,15,1].

Bone and endocrine interplay. Adequate intake supports bone mineralization directly and via the vitamin D–parathyroid hormone axis; epidemiology and interventional data link higher intake to higher bone mineral density and possibly lower fracture risk, though more definitive trials are needed [16–18].

Dietary Pattern and Top 15 Food Sources

A food‑first strategy can reliably meet daily needs while delivering fiber, potassium, and phytonutrients. Selected, commonly consumed options (serving sizes and milligrams per serving) include [1]:

1. Pumpkin seeds, roasted, 1 oz – 156 mg
2. Chia seeds, 1 oz – 111 mg
3. Almonds, dry roasted, 1 oz – 80 mg
4. Spinach, boiled, ½ cup – 78 mg
5. Cashews, dry roasted, 1 oz – 74 mg
6. Peanuts, oil roasted, ¼ cup – 63 mg
7. Shredded wheat cereal, 2 biscuits – 61 mg
8. Soymilk, 1 cup – 61 mg
9. Black beans, cooked, ½ cup – 60 mg
10. Edamame, cooked, ½ cup – 50 mg
11. Peanut butter, 2 tbsp – 49 mg
12. Potato with skin, 3.5 oz – 43 mg
13. Brown rice, cooked, ½ cup – 42 mg
14. Low‑fat yogurt, 8 oz – 42 mg
15. Whole‑wheat bread, 1 slice – 23 mg

For a comprehensive searchable database by food name or nutrient content, see USDA FoodData Central [2].

Supplement Forms, Dosing, and Safety

Forms and bioavailability. Absorption varies with solubility: organic salts (citrate, lactate, aspartate, chloride) generally demonstrate higher bioavailability than oxide and sulfate in small trials [1,19–21]. Citrate has shown superior bioavailability to oxide in both acute and short‑term studies, though long‑term clinical outcome differences remain uncertain [20,21].

General oral repletion (outpatient). For mild inadequacy or prevention in at‑risk adults, practical strategies include divided doses providing 200-400 mg elemental daily, titrated to minimize diarrhea (common with carbonate, chloride, gluconate, and oxide) [1,19–21]. Take chelating forms at different times of day from antibiotics and oral bisphosphonates [1].

Parenteral use (inpatient/ED). Follow specialty guidelines and institutional protocols: torsades protocols per AHA; obstetric seizure prophylaxis/treatment per ACOG; selective use in severe asthma per international guidance [6–8].

Safety and UL. Gastrointestinal intolerance (loose stools, cramping) is dose limiting. The adult UL for supplemental (non‑food) intake is 350 mg/day; foods are exempt. Toxicity is rare in normal renal function but can occur with very large intakes from laxatives/antacids or impaired excretion; manifestations include hypotension, depressed reflexes, and, at higher levels, bradyarrhythmias and arrest. Hypermagnesemia risk increases in advanced CKD, use caution and adjust dosing; in severe cases, stop exogenous sources and treat per standard electrolyte emergency protocols [1].

Drug interactions and monitoring. Separate dosing from tetracyclines/fluoroquinolones and oral bisphosphonates; assess for diuretic‑related wasting; review PPI exposure and monitor or deprescribe if feasible with specialty input [1,22].

Practical Counseling for U.S. Clinicians

1. Start with diet. Encourage seeds, nuts, legumes, whole grains, and leafy greens; leverage fortified cereals and soymilk when appropriate; address food access and preferences [1].
2. Screen contextually. In arrhythmias, refractory hypokalemia/hypocalcemia, or at‑risk states (T2D, GI disease, diuretics, prolonged PPI), check and correct; consider erythrocyte or 24‑hour urinary testing in persistent diagnostic uncertainty [1,5,22].
3. Use supplements judiciously. Choose better‑absorbed forms when GI tolerance allows; counsel on dose timing and UL; monitor renal function and adverse effects [1,19–21].
4. Apply specialty guidance. Follow AHA for torsades, ACOG for preeclampsia/eclampsia, and GINA for severe asthma exacerbations; document indication and response [6–8,7].

Key Takeaways

• This ubiquitous cofactor underpins neuromuscular, cardiac, metabolic, and skeletal physiology; population intake shortfalls are common in the U.S. [1].
• Serum testing alone can miss tissue depletion; consider risk profile, co‑electrolytes, and targeted testing [1,4,5].
• Acute, guideline‑based parenteral therapy saves lives in torsades and eclampsia; preventive roles (e.g., migraine, modest BP effects) are supported with caveats [6–11].
• Food‑first approaches, judicious supplementation, interaction management, and renal‑aware safety practices form the backbone of care [1,19–22].

References

Core Background & U.S. Status
[1] “Magnesium – Health Professional Fact Sheet,” NIH Office of Dietary Supplements, June 2, 2022.
[2] “USDA FoodData Central,” U.S. Department of Agriculture, Accessed 2025.
[3] de Baaij JHF, Hoenderop JGJ, Bindels RJM., “Magnesium in Man: Implications for Health and Disease,” Physiological Reviews (2015).
[4] Rosanoff A. et al., “Recommendation on an updated standardization of serum magnesium reference ranges,” European Journal of Nutrition (2022).
[5] Workinger JL. et al., “Challenges in the Diagnosis of Magnesium Status,” Nutrients (2018).

Acute Care Guidelines (Cardiology, Obstetrics, Pulmonology)
[6] “Gestational Hypertension and Preeclampsia. ACOG Practice Bulletin No. 222,” American College of Obstetricians and Gynecologists (May 2020) [PDF].
[7] Panchal AR. et al., “Part 3: Adult Basic and Advanced Life Support: 2020 American Heart Association Guidelines,” Circulation (2020).
[8] “GINA 2024 Strategy Report,” Global Initiative for Asthma (2024) [PDF].

Neurology & Headache
[9] “Incorporating Nutraceuticals for Migraine Prevention,” American Headache Society (April 15, 2021).
[10] Alharran AM. et al., “Impact of Magnesium Supplementation on Blood Pressure: Umbrella Meta-analysis,” 2024.
[11] Argeros Z. et al., “Magnesium Supplementation and Blood Pressure,” Hypertension (2025).

Mood & Metabolic Evidence
[12] Tarleton EK. et al., “Role of magnesium supplementation in the treatment of depression: A randomized clinical trial,” PLoS One (2017).
[13] Moabedi M. et al., “Magnesium supplementation and depression: a systematic review and meta-analysis,” Frontiers in Psychiatry (2023).
[14] Guerrero‑Romero F. et al., “Oral magnesium improves insulin sensitivity in insulin‑resistant subjects,” Diabetes & Metabolism (2004).
[15] Asbaghi O. et al., “Oral magnesium supplementation and glycaemic control in type 2 diabetes: systematic review and dose‑response meta‑analysis,” Clinical Nutrition Research (2022).

Bone & Vitamin D Interactions
[16] Uwitonze AM., Razzaque MS., “Role of Magnesium in Vitamin D Activation and Function,” JAOA (2018).
[17] Groenendijk IM. et al., “Impact of magnesium on bone health in older adults: systematic review and meta‑analysis,” Nutrition Research (2021).
[18] Hori M. et al., “Serum magnesium, bone mineral density, and fracture risk,” PLoS One (2021).

Formulations & Bioavailability; Safety
[19] Firoz M., Graber M., “Bioavailability of US commercial magnesium preparations,” Magnesium Research (2001).
[20] Walker AF. et al., “Mg citrate more bioavailable than other preparations: randomized double‑blind study,” Magnesium Research (2003).
[21] Kappeler D. et al., “Higher bioavailability of magnesium citrate compared with magnesium oxide,” BMC Nutrition (2017).
[22] U.S. FDA, “Drug Safety Communication: Low magnesium levels with long‑term PPI use,” March 2, 2011.